ALK-IN-26

CAS No. 2447607-85-2

ALK-IN-26( —— )

Catalog No. M37104 CAS No. 2447607-85-2

ALK-IN-26 is an ALK inhibitor with potential anticancer activity, demonstrating antiproliferative effects against glioblastoma and inducing apoptosis, autophagy, and necrosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 53 Get Quote
5MG 75 Get Quote
10MG 117 Get Quote
25MG 220 Get Quote
50MG 348 Get Quote
100MG 503 Get Quote
500MG 1071 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    ALK-IN-26
  • Note
    Research use only, not for human use.
  • Brief Description
    ALK-IN-26 is an ALK inhibitor with potential anticancer activity, demonstrating antiproliferative effects against glioblastoma and inducing apoptosis, autophagy, and necrosis.
  • Description
    ALK-IN-26 is an ALK inhibitor with IC50 value of 7.0 μM for ALK tyrosine kinase. ALK-IN-26 has good pharmacokinetic properties and blood-brain barrier (BBB) permeability. ALK-IN-26 can induce apoptosis, autophagy and necrosis. ALK-IN-26 can be used in glioblastoma studies.
  • In Vitro
    Apoptosis AnalysisCell Line:GL261 Concentration:0.5 μM, 1.0 μM, 2.0 μM Incubation Time:24 h, 48 h, 72 h Result:Induced apoptosis of glioblastoma in a concentration- and time-dependent manner, and caused the cells (24.5%) entered the S phase but barely proceeded to the G2/M phase when treated with 1 μM for 72 h.Cell Viability AssayCell Line:GL216, U87MG, HelaConcentration:0.5 μM, 1.0 μM, 2.0 μM, 5 μM, 10 μM for GL216 and U87MG cells 5 μM, 10 μM, 20 μM, 40 μM, 80 μM, 160 μM for Hela cells Incubation Time:24 h, 48h, 72h Result:Inhibited the activity of GL216 cells with the inhibition rate of cells at 80% when incubated with 2 μM for 72 h and inhibited U87MG cells viability with a dose- and time-dependent manner, while showed limited inhibition on Hela cells, even at 160 μM, the inhibition rate is less than 50%. Can inhibit the activity of ALK tyrosine kinase with a dose-dependent manner.Cell Autophagy Assay Cell Line:GL261 Concentration:0.5 μM, 1.0 μM, 2.0 μM Incubation Time:24 h Result: Induced autophagy death in glioblastoma cells.
  • In Vivo
    Animal Model:Male C57BL/6J miceDosage:5 mg/kgAdministration:Intravenous injection (i.v.), Single dose Result:Could be rapidly absorbed (Tmax = 0.58 h) with an acceptable half-life (T1/2 = 3.55 h) and bioavailability (F = 38.4%).Animal Model:Male C57BL/6J mice Dosage:20mg/kg Administration:Intraperitoneal injection (i.p.), Single doseResult:Could enter the body at concentrations up to 2.7μmol/kg (after 2 h administration at 20 mg/kg) andpenetrate the blood-brain barrier.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    ALK
  • Recptor
    ALK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2447607-85-2
  • Formula Weight
    405.51
  • Molecular Formula
    C24H23NO3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=S(=O)(C1=CC=C(C=C1)C)N2C=C(C=3C=CC=CC32)CC=4C=C(C(O)=C(C4)C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Feng L, et al. Synthesis and Bioevaluation of 3-(Arylmethylene) indole Derivatives: Discovery of a Novel ALK Modulator with Antiglioblastoma Activities[J]. Journal of Medicinal Chemistry, 2023.?
molnova catalog
related products
  • INCB-000928

    Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.

  • CH5424802 analog

    CH5424802 analog is a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

  • CEP-28122 mesylate

    A highly potent and selective, orally active ALK inhibitor with IC50 of 1.9 nM.